These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30166022)

  • 21. Immunotherapy for non-small cell lung cancer.
    Vafadar S
    JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
    Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
    [No Abstract]   [Full Text] [Related]  

  • 23. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
    Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
    Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
    [No Abstract]   [Full Text] [Related]  

  • 25. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Guihot A; Marcelin AG; Massiani MA; Samri A; Soulié C; Autran B; Spano JP
    Ann Oncol; 2018 Feb; 29(2):517-518. PubMed ID: 29206889
    [No Abstract]   [Full Text] [Related]  

  • 26. Nivolumab in non-small-cell lung cancer with EGFR mutation.
    Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
    Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
    [No Abstract]   [Full Text] [Related]  

  • 27. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Curioni-Fontecedro A; Ickenberg C; Franzen D; Rogler G; Burger IA; van den Broek M
    Ann Oncol; 2017 Aug; 28(8):2040-2041. PubMed ID: 28838208
    [No Abstract]   [Full Text] [Related]  

  • 28. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    Jin B; Chuang X; Liu Y
    J Thorac Oncol; 2018 Sep; 13(9):e174-e177. PubMed ID: 30166017
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
    Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
    [No Abstract]   [Full Text] [Related]  

  • 33. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
    Nakazawa N; Yokobori T; Turtoi A; Shirabe K
    Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
    [No Abstract]   [Full Text] [Related]  

  • 34. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report.
    Sarfaty M; Moore A; Dudnik E; Peled N
    Medicine (Baltimore); 2017 Jan; 96(4):e5951. PubMed ID: 28121940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab.
    Cabañero A; Gorospe L; Olmedo ME; Mezquita L
    Arch Bronconeumol (Engl Ed); 2019 Mar; 55(3):168-169. PubMed ID: 30017255
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report.
    Takemoto K; Miyahara N; Chikuie N; Hamamoto T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2019 Oct; 46(5):813-817. PubMed ID: 30442438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
    Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
    [No Abstract]   [Full Text] [Related]  

  • 39. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
    Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
    [No Abstract]   [Full Text] [Related]  

  • 40. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.